Immunohistochemical colocalization of the terminal complex of human complement and smooth muscle cell α-actin in early atherosclerotic lesions

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 11, 1997, Pages 2448-2452

  Torzewski, Michael ^d   Torzewski, Jan ^a,b   Bowyer, David E ^c   Waltenberger, Johannes ^a,b   Fitzsimmons, Colin ^c   Hombach, Vinzenz ^a,b   Gabbert, Helmut E ^d  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Division of Cellular Pathology ^*

Author keywords

Atherogenesis; C5b 9; Complement; Early lesions

Indexed keywords

ALPHA ACTIN;

ARTICLE; ATHEROSCLEROSIS; COMPLEMENT ACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOSTIMULATION; MONOCYTE; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; VASCULAR SMOOTH MUSCLE;

EID: 0031471223     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.11.2448     Document Type: Article

References (25)

1. Seifert PS, Kazatchkine MD. The complement system in atherosclerosis. Atherosclerosis. 1988;73:91-104.
2. Seifert PS, Hugo F, Hansson GK, Bhakdi S. Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincidences with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab Invest. 1989;60:747-757.
3. Bhakdi S, Dorweiler B, Kirchmann R, Torzewski J, Weise E, Tranum-Jensen J, Walev I, Wieland E. On the pathogenesis of atherosclerosis. Enzymatic transformation of human low-density to an atherogenic moiety. J Exp Med. 1995;182:1959-1971.
4. Torzewski J, Bowyer DE, Waltenberger J, Fitzsimmons C. Processes in atherogenesis: complement activation. Atherosclerosis. 1997;132:129-136.
5. Seifert PS, Hugo F, Tranum-Jensen J, Zähringer U, Muhly M, Bhakdi S. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med. 1990;172:547-557.
6. Torzewski J, Oldroyd R, Lachmann PJ, Fitzsimmons CI, Proudfoot D, Bowyer DE. Complement-induced release of monocyte chemotactic protein 1 from human SMC - a possible initiating event in atherosclerotic lesion formation. Arterioscler Thromb Vase Biol. 1996;16:673-677.
7. Kilgore KS, Flory CM, Miller BF, Evans VM, Warren JS. The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells. Am J Pathol. 1996;149:953-961.
8. Bhakdi S, Hugo F, Tranum-Jensen J. Functions and relevance of the terminal complement sequence. Blut. 1990;60:309-318.
9. Morgan BP. Complement. Clinical Aspects and Relevance to Disease. London: Academic Press Limited; 1990:1-49.
10. Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement protein C5b-9 releases bFGF and PDGF from endothelial cells. J Exp Med. 1994;179:985-992.
11. Morgan BP. Effects of the membrane attack complex on nucleated cells. Curr Top Microbiol Immunol. 1992;1787:1959-1971.
12. Seifert PS, Roth I, Schmid W, Oelert H, Okoda N, Okoda H, Bhakdi S. CD59 (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9-attack in human atherosclerotic lesions. Atherosclerosis. 1992;96:135-145.
13. Hollander W, Colombo MA, Kramsch DM, Kirkpatrick B. Soluble proteins in the human atherosclerotic plaque. With special reference to immunoglobulins, C3-complement component, α1-antitrypsin and α2-macroglobulin. Atherosclerosis. 1979;34: 391-405.
14. Hansson GK, Holm J, Kral IG. Accumulation of IgG and complement factor C3 in human arterial endothelium and atherosclerotic lesions. Acta Pathol Microbiol Immunol Scand Sect A. 1984;92:429-435.
15. Vlaicu R, Rus HG, Niculescu F, Cristea A. Immunoglobulins and complement components in human atherosclerotic intima. Atherosclerosis. 1985;55:35-50.
16. Vlaicu R, Niculescu F, Rus HG, Cristea A. Immunohistochemical localisation of the terminal C5b-9 complement complex in human aortic fibrous plaques. Atherosclerosis. 1985;57:163-167.
17. Rus HG, Niculescu F, Constaninescu E, Cristea A, Vlaicu R. Immunoelectronmicroscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque. Atherosclerosis. 1986;61:35-42.
18. Seifert PS, Roth I, Schmid W, Oelert H, Okoda N, Okoda H, Bhakdi S. CD59 (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9-attack in human atherosclerotic lesions. Atherosclerosis. 1992;96:135-145.
19. Rus HG, Niculescu F, Vlaicu R. Co-localization of terminal C5b-9 complement complexes and macrophages in human atherosclerotic arterial walls. Immunol Lett. 1988;19:27-32.
20. Rus HG, Niculescu F, Porutiu D, Ghiurca V, Vlaicu R. Cells carrying C5b-9 complement complexes in human atherosclerotic wall. Immunol Lett. 1989;20:305-310.
21. Stary HC. The histological classification of atherosclerotic lesions in human coronary arteries. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia: Lippincott-Raven Publishers; 1996:463.
22. Hugo F, Krämer S, Bhakdi S. Sensitive ELISA for quantitating the terminal membrane C5b-9 and fluid phase SC5b-9 complex of human complement. J Immunol Methods. 1987;99:243-251.
23. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between-ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580.
24. Niculescu F, Rus HG, Vlaicu R. Immunohistochemical localisation of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissue with atherosclerosis. Atherosclerosis. 1987:65:1-11.
25. Seifert PS, Hansson GK. Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions. J Clin Invest. 1989;84:597-604.